Please assess the completion status of the following clinical trial:

Trial Title: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on histologic examination.~* At least one objective measurable or evaluable disease parameter.~* Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Adequate renal function as indicated by creatinine \<= 1.5 the upper limit of normal (ULN).~* Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \<= 2x the upper limit of normal.~* Total bilirubin \<= 2x the upper limit of normal.~* Age 18 or older.~Exclusion Criteria:~* Prior cyclosporine or Tacrolimus (FK506).~* Prior allogeneic transplant.~* Evidence of active infection.~* Congestive heart failure, kidney failure, liver failure, or other severe co-morbidities.~* Evidence of active neurological impairment.~* Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL (polyoxyethylated oil).~* History of other malignancies (other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin).~* pregnant or breastfeeding women.~* Human immunodeficiency virus (HIV) positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporine (Type: EXPERIMENTAL): High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).